VYNE Therapeutics
VYNE
21 hedge funds and large institutions have $1.54M invested in VYNE Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
5% more funds holding
Funds holding: 20 → 21 (+1)
0.52% less ownership
Funds ownership: 12.22% → 11.69% (-0.52%)
5% less capital invested
Capital invested by funds: $1.63M → $1.54M (-$87.9K)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
US Bancorp
Minneapolis,
Minnesota
|
+$19.4K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.3K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.44K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.17K |
| 5 |
JP Morgan Chase
New York
|
+$602 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$44.1K |
| 2 |
BlackRock
New York
|
-$18.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.94K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.39K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.66K |
VYNE Hedge Fund Activity: Q3 2023 in Review
21 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q3 2023, worth a combined $1.54M — down 5.4% from $1.63M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new VYNE positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 7 trimmed.
The largest buyer was US Bancorp, opening a new position worth an estimated $19.4K. The largest seller was Renaissance Technologies, cutting an estimated $44.1K.
- 21 institutional investors held VYNE Therapeutics (VYNE) as of Q3 2023, up from 20 in Q2 2023.
- Funds reported $1.54M of VYNE Therapeutics stock for Q3 2023, down 5.4% quarter-over-quarter.
- 3 funds opened new VYNE Therapeutics positions in Q3 2023 and 1 closed out, a net change of +2 holders.
- The largest VYNE Therapeutics buyer in Q3 2023 was US Bancorp, an estimated $19.4K added.
- The largest VYNE Therapeutics seller in Q3 2023 was Renaissance Technologies, an estimated $44.1K sold.
Based on aggregated 13F filings for Q3 2023.